REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Research/Paper
Back to Research Library
PubMedMeta-Analysis

Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.

Karagiannis Thomas, Avgerinos Ioannis, Liakos Aris, Del Prato Stefano, Matthews David R, Tsapas Apostolos, Bekiari Eleni
Diabetologia2022DOI: 10.1007/s00125-022-05715-4

Citations

0

Subjects

Non-Human

Study Context

Meta-analyses statistically combine data from multiple independent studies to increase statistical power and precision. By pooling results, they can detect effects that individual studies may be too small to identify.

What This Study Type Means

  • Increased statistical power from combined sample sizes
  • Can resolve conflicting results across individual studies
  • Quantifies overall effect size with confidence intervals
  • Heterogeneity analysis reveals how consistent findings are across studies

Evidence Reliability: Very High — meta-analyses provide the most precise estimate of treatment effects

Why This Matters

This research examines Tirzepatide and Semaglutide, providing data that spans multiple peptide compounds. Cross-peptide research helps identify synergistic effects, comparative efficacy, and shared mechanisms of action.

TirzepatideSemaglutide

How to Interpret This Research

1

Look for the sample size — larger studies produce more reliable results. Single-digit sample sizes warrant caution.

2

Check whether the study was funded by a pharmaceutical company or conducted independently, as funding sources can influence study design and reporting.

3

Always consult a qualified healthcare provider before making treatment decisions based on research findings. Published research is not a substitute for personalized medical advice.

Citation

Karagiannis Thomas, Avgerinos Ioannis, Liakos Aris et al.. (2022). Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.. Diabetologia. https://doi.org/10.1007/s00125-022-05715-4

View full text on PubMed

Related Papers

Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.

Mendias Christopher L et al.· Sports medicine (Auckland, N.Z.)· 2026Review

From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management.

Yuan Claire et al.· International journal of molecular sciences· 2026Review

Carbonless amino acids and a carbonless GHK peptide.

Skurski Piotr et al.· Physical chemistry chemical physics : PCCP· 2026Review

The GHK-Cu delays aging in Caenorhabditis elegans via coordinated regulation of mitochondrial function and activation of DAF-16/SKN-1 pathways.

Wen Huijun et al.· Biogerontology· 2026Review

Glycyl-L-histidyl-L-lysine-Cu2

Hu Jing et al.· European journal of pharmacology· 2026Review

Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.

Mayfield Cory K et al.· The American journal of sports medicine· 2026Review

Explore Further

Research Library

Browse all indexed papers

Research Guides

Plain-language peptide guides

This content is derived from peer-reviewed research for educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide-based therapy.